DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,367 filers reported holding DANAHER CORPORATION in Q1 2019. The put-call ratio across all filers is 1.02 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $751,367 | -6.2% | 3,028 | -9.3% | 0.09% | -3.2% |
Q2 2023 | $800,978 | -3.4% | 3,337 | +1.5% | 0.10% | -7.8% |
Q1 2023 | $828,790 | -2.4% | 3,288 | 0.0% | 0.10% | -15.6% |
Q3 2022 | $849,000 | -8.2% | 3,288 | -5.7% | 0.12% | -0.8% |
Q2 2022 | $925,000 | +1.4% | 3,488 | -1.7% | 0.12% | +9.8% |
Q1 2022 | $912,000 | -25.2% | 3,547 | -4.3% | 0.11% | -19.4% |
Q4 2021 | $1,220,000 | +9.3% | 3,708 | +1.2% | 0.14% | -7.3% |
Q3 2021 | $1,116,000 | +4.7% | 3,665 | -0.3% | 0.15% | -3.8% |
Q2 2021 | $1,066,000 | +28.9% | 3,675 | 0.0% | 0.16% | +16.4% |
Q1 2021 | $827,000 | -8.8% | 3,675 | -3.9% | 0.13% | -14.1% |
Q4 2020 | $907,000 | +8.6% | 3,825 | -1.4% | 0.16% | -7.7% |
Q3 2020 | $835,000 | +20.3% | 3,880 | -1.3% | 0.17% | +0.6% |
Q2 2020 | $694,000 | +45.5% | 3,930 | +13.9% | 0.17% | +50.0% |
Q1 2020 | $477,000 | -12.6% | 3,450 | -3.1% | 0.11% | 0.0% |
Q4 2019 | $546,000 | +4.2% | 3,560 | -1.9% | 0.11% | -5.1% |
Q3 2019 | $524,000 | -8.1% | 3,630 | -9.0% | 0.12% | -10.6% |
Q2 2019 | $570,000 | -3.2% | 3,990 | -10.6% | 0.13% | -5.7% |
Q1 2019 | $589,000 | +20.2% | 4,465 | -6.1% | 0.14% | +17.6% |
Q4 2018 | $490,000 | -5.0% | 4,755 | 0.0% | 0.12% | -4.8% |
Q3 2018 | $516,000 | +10.0% | 4,755 | 0.0% | 0.12% | +2.5% |
Q2 2018 | $469,000 | -3.3% | 4,755 | -4.0% | 0.12% | -7.6% |
Q1 2018 | $485,000 | +5.0% | 4,955 | -0.6% | 0.13% | +7.3% |
Q4 2017 | $462,000 | +8.2% | 4,985 | 0.0% | 0.12% | +3.4% |
Q3 2017 | $427,000 | +1.7% | 4,985 | 0.0% | 0.12% | +0.8% |
Q2 2017 | $420,000 | -1.4% | 4,985 | 0.0% | 0.12% | -7.8% |
Q1 2017 | $426,000 | +9.8% | 4,985 | 0.0% | 0.13% | -0.8% |
Q4 2016 | $388,000 | -0.5% | 4,985 | 0.0% | 0.13% | -3.0% |
Q3 2016 | $390,000 | -20.9% | 4,985 | +2.0% | 0.13% | -30.7% |
Q2 2016 | $493,000 | +4.9% | 4,885 | -1.6% | 0.19% | +22.3% |
Q1 2016 | $470,000 | +2.0% | 4,965 | 0.0% | 0.16% | -2.5% |
Q4 2015 | $461,000 | +8.2% | 4,965 | -0.8% | 0.16% | -9.0% |
Q3 2015 | $426,000 | -0.5% | 5,005 | 0.0% | 0.18% | +5.4% |
Q2 2015 | $428,000 | +1.7% | 5,005 | +0.8% | 0.17% | +42.4% |
Q1 2015 | $421,000 | -1.6% | 4,965 | -0.8% | 0.12% | -26.7% |
Q4 2014 | $428,000 | +2.4% | 5,005 | -9.1% | 0.16% | +9.5% |
Q3 2014 | $418,000 | -6.9% | 5,505 | -3.5% | 0.15% | -13.5% |
Q2 2014 | $449,000 | +3.2% | 5,705 | -1.6% | 0.17% | -1.7% |
Q1 2014 | $435,000 | -65.8% | 5,800 | -64.8% | 0.17% | -32.7% |
Q4 2013 | $1,272,000 | +112.0% | 16,500 | +90.8% | 0.26% | -4.5% |
Q3 2013 | $600,000 | +7.7% | 8,650 | -1.7% | 0.27% | +4.3% |
Q2 2013 | $557,000 | – | 8,800 | – | 0.26% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |